OBJECTIVE: Patients with type 1 diabetes now live long enough to experience cognitive decline. During middle age, they show mild cognitive deficits, but it is unknown whether severity increases with aging or whether cognitive profiles are similar to those of age-matched peers with and without diabetes. RESEARCH DESIGN AND METHODS: We tested and compared cognition in 82 individuals with 50 or more years of type 1 diabetes (Medalists), 31 age-matched individuals with type 2 diabetes, and 30 age-matched control subjects without diabetes. Medical histories and biospecimens were collected. We also evaluated the association of complications with cognition in Medalists only. RESULTS: Compared with control subjects, both individuals with type 1 diabetes and individuals with type 2 diabetes performed worse on immediate and delayed recall (P ≤ 0.002) and psychomotor speed in both hands (P ≤ 0.01) and showed a trend toward worse executive function (P = 0.05). In Medalists, cardiovascular disease was associated with decreased executive function and proliferative diabetic retinopathy with slower psychomotor speed. CONCLUSIONS: Both patients with type 1 and patients with type 2 diabetes showed overall worse cognition than control subjects. Further, in Medalists, a relationship between complications and cognition was seen. Although both groups with diabetes showed similar deficit patterns, the underlying mechanisms may be different. Now that patients with type 1 diabetes are living longer, efforts should be made to evaluate cognition and to identify modifying behaviors to slow decline.
OBJECTIVE: Patients with type 1 diabetes now live long enough to experience cognitive decline. During middle age, they show mild cognitive deficits, but it is unknown whether severity increases with aging or whether cognitive profiles are similar to those of age-matched peers with and without diabetes. RESEARCH DESIGN AND METHODS: We tested and compared cognition in 82 individuals with 50 or more years of type 1 diabetes (Medalists), 31 age-matched individuals with type 2 diabetes, and 30 age-matched control subjects without diabetes. Medical histories and biospecimens were collected. We also evaluated the association of complications with cognition in Medalists only. RESULTS: Compared with control subjects, both individuals with type 1 diabetes and individuals with type 2 diabetes performed worse on immediate and delayed recall (P ≤ 0.002) and psychomotor speed in both hands (P ≤ 0.01) and showed a trend toward worse executive function (P = 0.05). In Medalists, cardiovascular disease was associated with decreased executive function and proliferative diabetic retinopathy with slower psychomotor speed. CONCLUSIONS: Both patients with type 1 and patients with type 2 diabetes showed overall worse cognition than control subjects. Further, in Medalists, a relationship between complications and cognition was seen. Although both groups with diabetes showed similar deficit patterns, the underlying mechanisms may be different. Now that patients with type 1 diabetes are living longer, efforts should be made to evaluate cognition and to identify modifying behaviors to slow decline.
Authors: Yuji Okura; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Richard J Rodeheffer Journal: J Clin Epidemiol Date: 2004-10 Impact factor: 6.437
Authors: Eelco van Duinkerken; Augustina M A Brands; Esther van den Berg; Johanna M L Henselmans; Roel P L M Hoogma; Geert Jan Biessels Journal: J Am Geriatr Soc Date: 2011-03 Impact factor: 5.562
Authors: Augustina M A Brands; Roy P C Kessels; Roel P L M Hoogma; Johanna M L Henselmans; Johanna W van der Beek Boter; L Jaap Kappelle; Edward H F de Haan; Geert Jan Biessels Journal: Diabetes Date: 2006-06 Impact factor: 9.461
Authors: Jordi Peña-Casanova; Gonzalo Sánchez-Benavides; Susana de Sola; Rosa Maria Manero-Borrás; Marta Casals-Coll Journal: Arch Med Res Date: 2012-10-13 Impact factor: 2.235
Authors: Wendy A Davis; Renate R Zilkens; Sergio E Starkstein; Timothy M E Davis; David G Bruce Journal: Diabetologia Date: 2016-10-07 Impact factor: 10.122
Authors: Alanna Weisman; Leif E Lovblom; Hillary A Keenan; Liane J Tinsley; Stephanie D'Eon; Genevieve Boulet; Mohammed A Farooqi; Julie A Lovshin; Andrej Orszag; Yuliya Lytvyn; Michael H Brent; Narinder Paul; Vera Bril; David Z Cherney; Bruce A Perkins Journal: Diabetes Care Date: 2017-11-08 Impact factor: 19.112
Authors: Bruce A Perkins; Leif Erik Lovblom; Sebastien O Lanctôt; Krista Lamb; David Z I Cherney Journal: Diabetologia Date: 2021-03-04 Impact factor: 10.122
Authors: Ward Fickweiler; Emily A Wolfson; Samantha M Paniagua; Marc Gregory Yu; Atif Adam; Vanessa Bahnam; Konstantina Sampani; I-Hsien Wu; Gail Musen; Lloyd P Aiello; Hetal Shah; Jennifer K Sun; George L King Journal: J Clin Endocrinol Metab Date: 2021-03-25 Impact factor: 5.958
Authors: Allison L B Shapiro; Dana Dabelea; Jeanette M Stafford; Ralph D'Agostino; Catherine Pihoker; Angela D Liese; Amy S Shah; Anna Bellatorre; Jean M Lawrence; Leora Henkin; Sharon Saydah; Greta Wilkening Journal: Diabetes Care Date: 2021-04-26 Impact factor: 17.152
Authors: Nelly Mauras; Bruce Buckingham; Neil H White; Eva Tsalikian; Stuart A Weinzimer; Booil Jo; Allison Cato; Larry A Fox; Tandy Aye; Ana Maria Arbelaez; Tamara Hershey; Michael Tansey; William Tamborlane; Lara C Foland-Ross; Hanyang Shen; Kimberly Englert; Paul Mazaika; Matthew Marzelli; Allan L Reiss Journal: Diabetes Care Date: 2021-02-10 Impact factor: 19.112